Cytel’s East Alloy platform is a web-native extension of the company’s East software for adaptive clinical trial design and analysis.
By leveraging the speed of cloud computing and the pace of SaaS delivery, East Alloy enables easy implementation of computationally intensive Bayesian methods that may be otherwise impractical. To support the launch, Cytel will also host a 60-minute webinar on July 29 introducing East Alloy and detailing how it can be used to adopt Bayesian and innovative methods with speed and confidence.
Amidst the rapid pace of modern clinical development, drug developers are increasingly seeking greater clinical trial efficiency and probability of success while also minimising costs. This often means turning to sophisticated and innovative clinical trial designs, including Bayesian methods. However, underpowered on-premise technology can make execution of such methods challenging under routine statistical design timelines. Furthermore, publicly available solutions often rely on unverified bespoke coding, which can introduce risk to clinical programs.
“As trial designers turn to open-source or home-grown trial design solutions to meet the demands of modern drug development, they’re experiencing a range of challenges, from a lack of user-friendliness and quality control, to difficulty accessing the computational power needed to deploy these complex methods,” commented Yannis Jemiai, Chief Scientific Officer at Cytel. “With East Alloy, we’re combining Cytel-curated public solutions that we’ve subjected to our robust verification program with Cytel’s own cutting-edge engines, and then accelerating their delivery via SaaS and cloud computing. This enables our customers to avoid extensive IT infrastructure and confidently deploy powerful innovative techniques and Bayesian methods with ease.”
Bayesian methods are of growing interest to the drug development industry, as they allow clinical investigators to leverage historical trial data as well as learnings from new data as it accrues throughout a trial. The result is better-informed decision making, greater program flexibility, and the ability to run smaller, more resource-efficient trials.
“Our longstanding dedication to adaptive Bayesian approaches means we’re perfectly placed to meet and exceed the growing innovation needs of the pharmaceutical sector,” said Pantelis Vlachos, Director and Strategic Consultant at Cytel. “But it’s key to ensure our customers can practically implement this kind of innovation. East Alloy, reinforced by industry-leading verification, training, and support from Cytel experts, means users can sustainably adopt Bayesian designs to expedite clinical development and overcome uncertainty without compromising scientific rigour.”
